The Danish pharmaceuticals published her balance for the first quarter of the year, with positive results in part thanks to the diabetes and obesity business.
Novo Nordisk published on the day of the date his results for the first three months of the year, where he registered an increase in its 10%profits.
As detailed by the company, its sales increased 5% in local currency.The net profit for the first three months of the year was 1,366 million euros, compared to 1,272 million euros a year ago.
The high points were the diabetes and obesity segment care to compensate for a fall in its division of biopharmaceutical products, which novo Nordisk said suffered from the recent introduction of a generic version of one of its treatments of menopause in the US and an effectin chain of the United States discount settings in the first quarter of last year.
The company's executive president, Mr. Fruerdaard said with the performance in the first three months, we are on the right track towards our goals for 2017. Sales were promoted by our new products, innovative within diabetes and care for careObesity, and we are seeing the effects of our initiative cost control, which allows us to invest in opportunities for future growth¨.
The new generation insulins were the company's spearhead, and promoted 163% compared to the first quarter of the previous year.This segment highlighted its Ryzodeg, Tresiba and Xultophy brands.
The negative appearance was given by its biopharmaceuticals unit, which registered a drop in their -25%sales, mainly due to the recent launch of a generic version of Vagifem, its product to reduce the vaginal symptoms of menopause, in the United States.
